(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 2.57% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Enanta Pharmaceuticals's revenue in 2025 is $64,806,000.On average, 8 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,426,292,267, with the lowest ENTA revenue forecast at $1,225,596,326, and the highest ENTA revenue forecast at $1,607,192,251. On average, 6 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,465,392,488, with the lowest ENTA revenue forecast at $1,148,293,756, and the highest ENTA revenue forecast at $1,728,405,075.
In 2028, ENTA is forecast to generate $1,493,055,520 in revenue, with the lowest revenue forecast at $999,011,720 and the highest revenue forecast at $2,199,788,277.